This year’s Verona Pharma AGM was held at 9.00 a.m. on Wednesday 2nd May 2018 at The London offices of NASDAQ, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA For investors who are unfamiliar with the company, Verona is a clinical stage Pharmaceutical company currently focused on developing just one asset, RPL554, which has a unique mechanism of action (PDE3/PDE4 inhibition). RPL554 is currently being developed for the treatment of COPD and Cystic Fibrosis. The company listed on Aim in 2006 through a reverse takeover of Isis Resources, raising around £2m at 4p/share, which valued the company at just under £6m. There have been numerous equity based fund raisings since 2006, including an IPO on Nasdaq (raising £70m) which took place just after a one for fifty share consolidation. The
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.